Two cases of mild systemic adverse skin eruption after coronavirus disease 2019 vaccination

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

“…Histopathologic studies on post–COVID vaccination revealed erythematous, maculopapular, and morbilliform rashes with perivascular and perifollicular lymphohistiocytic infiltrates, 35,41–47 neutrophils, and abundant eosinophils in the epidermis, 35,43 spongiosis, basal cell vacuolization, 42,43,46 and apoptotic cells, 43,47 with morbilliform erythema. Histopathology of erythematous maculopapular plaques or patches were reported as follows: inflammatory infiltrates within dermis primarily including lymphocytes, eosinophils, and occasional histiocytes, 38,42,43,48–53 spongiosis, RBCs extravasation, 38,42,44,48,52,53 widened rete ridges, 54 orthokeratosis, parakeratosis, 38,45,54 and vacuolization of basal layer cells. 38,43…”

“…39 Erythematous/Maculopapular/Morbilliform Rash Histopathologic studies on post-COVID vaccination revealed erythematous, maculopapular, and morbilliform rashes with perivascular and perifollicular lymphohistiocytic infiltrates, 35,[41][42][43][44][45][46][47] neutrophils, and abundant eosinophils in the epidermis, 35,43 spongiosis, basal cell vacuolization, 42,43,46 and apoptotic cells, 43,47 with morbilliform erythema. Histopathology of erythematous maculopapular plaques or patches were reported as follows: inflammatory infiltrates within dermis primarily including lymphocytes, eosinophils, and occasional histiocytes, 38,42,43,[48][49][50][51][52][53] spongiosis, RBCs extravasation, 38,42,44,48,52,53 widened rete ridges, 54 orthokeratosis, parakeratosis, 38,45,54 and vacuolization of basal layer cells. 38,43 In 3 studies, a sample was taken from an erythematous nodule on the injection site and histopathology displayed nodular infiltration of mature lymphocytes and rare blasts in the superficial and deep dermis with occasional extension to the basal cells layer, Civatte bodies, and spongiosis.…”

SARS‐CoV‐2 vaccine‐related cutaneous manifestations: a systematic review

“…In cases where the same sample was used for more than one study, all studies were reviewed to determine the extent to which there may be duplication in the reported outcomes between studies. The full text of selected studies was reviewed, and data on demographics, article type, number of reported cases with cutaneous involvement, vaccine, and rash type (morphology) were extracted from articles texts, tables, figures, and summarized through a descriptive table (Table 1)…”

“…9 ), 2 Pfizer (Farinazzo et al234 ), 42 Moderna (McMahon et al138 ), 23 Pfizer (McMahon et al138 ), 1 JJ (McMahon et al138 ), 1 Astrazeneca (McMahon et al138 ), 3 Not specified (McMahon et al138 ), 1 Pfizer (Ackerman et al32 ), 1 Pfizer (Rojas-P erez-Ezquerre et al35 ), 1 Pfizer (Ohsawa et al66 ), 1 Moderna (Larson et al92 ), 2 Pfizer (Annabi et al108 ), 1 Moderna (Holmes et al124 ), 1 Pfizer (Tihy et al130 ), 5 Pfizer (Peigottu et al158 ), 5 Coronavac (Rerknimitr et al175 ), 1 Astrazeneca (Rerknimitr et al175 ), 1 Not specified (Grieco et al192 ), 2 Pfizer (Nanamori et al189 ), 3 Coronavac (Yu et al204 ), 1 Astrazeneca (Yu et al204 ), 2 Moderna (Juarez Guerrero et al230 ), 5 Pfizer (Juarez Guerrero et al230 ) 234. ),13 Moderna (McMahon et al 138 ), 6 Pfizer (McMahon et al 138 ), 2 Astrazeneca (McMahon et al 138 ), 3 Not specified (McMahon et al138 ), 2 Pfizer (Busto-Leis et al20 ), 1 Pfizer (Carballido-V azques et al22 ), 1 Coronavac (Akdas et al26 ), 2 Pfizer (Cyrenne et al40 ), 1 Pfizer (Abdullah et al56 ), 1 Covishield (Adya et al64 ), 2 Pfizer (Marcantonio-Santa Cruz et al82 ), 1 Moderna (Larson et al92 ), 14 Pfizer (Temiz et al110 ), 17 Coronavac (Temiz et al110 ), 1 Coronavac (Akdas et al112 ), 8 Coronavac (Durmaz et al118 ), 1 Pfizer (Cohen et al…”

Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine

“…A 48‐year‐old female experienced a cutaneous adverse reaction 3 days after the second administration of the COVID‐19 vaccine, as previously described. 7 She exhibited generalized erythematous plaques on her trunk and extremities, without mucosal eruption. She desired a third administration of the BioNTech COVID‐19 vaccine (Pfizer) to prevent infection.…”